Literature DB >> 25221715

Virtual Elimination of Mother-to-Child Transmission of Human Immunodeficiency Virus in Mothers on Highly Active Antiretroviral Therapy in Enugu, South-Eastern Nigeria.

Ii Okafor1, Eo Ugwu2, Sn Obi2, Bu Odugu1.   

Abstract

BACKGROUND: With the current World Health Organization (WHO) "Option B+" for prevention of mother to child transmission (PMTCT) of human immunodeficiency virus (HIV), virtual elimination of mother to child transmission (eMTCT) is highly achievable. AIM: The aim of this study is to determine the rate of MTCT of HIV from mothers who started highly active antiretroviral therapy (HAART) for life from diagnosis during pregnancy to the exposed babies who had daily nevirapine in the first 6 weeks of life. SUBJECTS AND METHODS: HIV positive mothers and their exposed babies who enrolled for the hospital PMTCT protocol from January 1, 2009 to December 31, 2011 were studied. The babies were tested for HIV using deoxyribo nucleic acid polymerase chain reaction test at 6 weeks, and then HIV rapid tests at 18 months.
RESULTS: A total of 5,946 booked mothers had HIV testing and counseling (HTC) within the study period. Two hundred and twenty-three (223/5946, 3.7%) were positive, out of which 188 (188/223, 84.3%) enrolled for the PMTCT interventions while 35 (35/223, 15.7%) did not enroll. Three of the enrollees were lost to follow up and two were referred to another PMCT center. Of the remaining 183 enrolled HIV positive mothers, one gave birth to a set of twins, giving a total of 184 exposed babies. There were two cases of intrauterine fetal death of unknown fetal HIV status. None of the 182 remaining babies evaluated for HIV testing tested positive to HIV.
CONCLUSIONS: With adequate suppression of maternal viral replication with HAART using the WHO Option B+, eMTCT of HIV is achievable in a developing country like Nigeria where infant breastfeeding is a norm.

Entities:  

Keywords:  Developing country; Elimination of mother to child transmission; Highly active antiretroviral therapy; Human immunodeficiency virus

Year:  2014        PMID: 25221715      PMCID: PMC4160691          DOI: 10.4103/2141-9248.139344

Source DB:  PubMed          Journal:  Ann Med Health Sci Res        ISSN: 2141-9248


Introduction

Without prevention of mother to child transmission (PMTCT) interventions, the rate of maternal to child transmission (MTCT) of human immunodeficiency virus (HIV) ranged from 25% to 35%.[1] Transmission can occur in pregnancy, delivery, and during breastfeeding periods. High maternal viral loads, vaginal delivery, prolonged rupture of fetal membranes, low CD4 cell counts, and prolonged breastfeeding were implicated in MTCT of HIV in the era of inadequate maternal viral suppression with antiretroviral monotherapy.[2345] Other risk factors include short duration of antiretroviral therapy (ART) before delivery and poor adherence to treatment. Major breakthroughs in MTCT of HIV started in 1994 when 67% reduction in MTCT of HIV was achieved with antenatal, intra-partum and infant zidovudine (AZT) monotherapy and formula feeding in the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group 076 study.[6] In 1999, 47% reduction was achieved with single-dose nevirapine (sdNVP) simpler regimens (HIVNET 012).[7] The addition of sdNVP to “Thai AZT Regimen” in 2003, dramatically reduced transmission to only 2-3% in non-breast feeding population with higher MTCT of HIV of about 5-6% in a breastfeeding population.[8] Previously, elective caesarean delivery was often recommended in order to reduce the risk of MTCT when the viral load is detectable or >1000 copies/mL[910] However, with the current era of World Health Organization (WHO) Option B+ for highly active antiretroviral therapy (HAART) - based PMTCT interventions, the benefits of elective caesarean delivery, limiting the rupture of fetal membranes to <4 h duration, and limiting breast feeding to the first 6-12 months of life are doubtful in view of the possibility of maximal viral suppression achievable with the intervention.[1112] The current WHO Option B and B+ for HAART - based PMTCT interventions have shown that with adequate suppression of maternal viral replication, virtual elimination of maternal to child transmission (eMTCT) to <2% is achievable by 2015.[1314] This option was introduced because replacement infant feeding in developing countries, became a big obstacle because of the associated social, cultural, economic, hygienic, and stigmatization problems.[15] The current WHO Option B and B+ for HAART - based PMTCT interventions whereby breastfeeding is allowed for up to 12 months with the mother on HAART and the infant on daily NVP in the first 6 weeks, is anticipated to have a positive impact on MTCT reduction especially in breastfeeding population like Nigeria.[16] There is a paucity of data in Nigeria on the rate of MTCT of HIV following this new method of PMTCT intervention and there is no study in this regard from the study area. This study therefore aimed at determining the rate of MTCT of HIV from mothers who started HAART for life from diagnosis during pregnancy to the exposed babies who had daily NVP in the first 6 weeks of life.

Subjects and Methods

Setting

Enugu State University Teaching Hospital Parklane (ESUTHP) Enugu is a state owned health institution that evolved from Nursing Home in 1930 for the colonial masters to a teaching hospital status in June 2006. Pregnant women book for antenatal care in this institution only on Thursdays. The women and few of the accompanying husbands were given group HIV counseling in the antenatal hall and their questions answered by the PMTCT nurse counselor. Filled routine investigation forms (including HIV tests for women and their husbands) were given to them. The HIV tests were done the same day by laboratory scientists attached to the departmental side laboratory and the results released to the clients the same day through the PMTCT nurses. Individual counseling was only given to HIV positive mothers and their husbands the same day because of limited manpower and rooms for counseling. The HIV positive clients were given an appointment on the days the PMTCT coordinator runs antenatal clinic. The PMTCT clinic is integrated with the normal antenatal clinic to avoid stigmatization. Enugu state university teaching hospital parklane highly active antiretroviral therapy - based prevention of mother to child transmission protocol.

Inclusion criteria

These included booked HIV positive mothers, who had HAART during pregnancy, labor, and breastfeeding periods. Also included were their HIV exposed babies who had NVP or AZT prophylaxis in their first 6 weeks of life. Exclusion criteria: These involved all unbooked HIV positive women, and all the booked HIV positive women who commenced HAART for <4 months before delivery.

Enugu state university teaching hospital parklane highly active antiretroviral therapy - based prevention of mother to child transmission protocol

This ESUTHP HAART-based PMTCT protocol was designed and used in this institution since its activation to a comprehensive HIV/AIDS site in January 1, 2009. The protocol involves routine HIV testing and counseling on the Thursday antenatal booking clinic and also in the labor ward for unbooked mothers presenting in labor, but the mothers have right to opt out. For mothers who tested negative at booking, HIV retesting was scheduled at 28-36 weeks gestation. Partners and family HIV testing and counseling (HTC) were planned for mothers who tested positive at booking or at the 28-36 weeks gestation. Tuberculosis and opportunistic infections screenings together with co-trimoxazole prophylaxis for Pneumocystic carina pneumonia infection were also offered to HIV positive mothers. Other basic antenatal services like tetanus toxoid immunization, intermittent preventive treatment for malaria using sulfadoxine pyrimethamine, and routine drugs were given to women. In addition, they were encouraged to sleep under the insecticide treated nets. The HIV positive mothers were commenced on HAART after 14 weeks of gestation, which they continued on during labor, breastfeeding and also after cessation of breast feeding irrespective of CD4 count levels and clinical staging. The common first line HAART regimen used in the facility were a combination of AZT, lamuvidine (3TC) and NVP when CD4 count was <250 cells/mL; AZT, 3TC and efavirenz (EFV) (when gestational age is >14 weeks); and 3TC, EFV and tenofovir disoproxil fumarate. The HIV exposed babies were given daily NVP from birth till 6 weeks of age. Family planning services were provided for them after delivery and their neonates were offered routine infant immunization. Three trained PMTCT nurses routinely tracked and monitored the HIV positive mothers and their exposed babies through home visits and phone calls. The HIV exposed babies were also followed up on Wednesday clinic by the trained consultant pediatricians. Babies’ blood samples were taken to Nnamdi Azikiwe Teaching Hospital Nnewi, Anambra state for HIV deoxyribo nucleic acid polymerase chain reaction (PCR) test at 6 weeks. At 18 months of age, HIV testing was repeated using HIV rapid test at the ESUTHP, Enugu. Furthermore, the antenatal booking registers of the HIV positive mothers and that of the paired case notes of their exposed infants were reviewed and relevant data analyzed by simple proportions and percentages. The study was approved by the relevant ethical committee of the hospital.

Results

A total of 5946 booked mothers had HTC within the study period. Five thousand seven hundred and twenty-three (5723/5946, 96.3%) mothers tested negative to HIV. Two hundred and twenty-three (223/5946, 3.7%) mothers tested positive out of which 188 (188/223, 84.30%) enrolled for the PMTCT interventions while 35 (35/223, 15.70%) did not enroll because they were already receiving antiretroviral drugs in other facilities. Three of the enrollees were lost to follow-up and 2 were referred to another facility for PMTCT on request. The mean age of the patients was 28.8 (4.1), and most (91.3%, 167/183) were ≤35 years, married (97.8%, 179/183), had secondary education (70.5%, 129/183), and multiparous (69.4%, 127/183). Details of the socio-demographic characteristics of the patients were as shown in Table 1. Of the 183 HIV positive mothers recruited, one gave birth to a set of twins, giving a total of 184 exposed babies. Two HIV positive mothers with singleton gestations had unexplained intrauterine fetal death at term. The HIV status of the stillborn babies was unknown. A total of 166 (90.71%) mothers were delivered vaginally, while 9.3% (n = 3) had a cesarean delivery. Most of the babies (91.8%, 167/182) had exclusive breastfeeding while 5.5% (10/182) were on mixed breastfeeding and 2.7% (5/182) on breast milk substitute.
Table 1

Sociodemographic characteristics of the patients

Sociodemographic characteristics of the patients The HIV testing at 6 weeks for the 182 live births was negative. Four babies that tested negative to HIV testing at 6 weeks died before the age of 18 months following acute illnesses. Two died from acute diarrheal diseases, one from severe malaria, and one from undiagnosed cause. The HIV testing at 18 months for the remaining 178 babies was negative.

Discussion

A total of 182 out of 184 HIV exposed babies (98.9%) tested negative at 18 months. The HIV status of the remaining two exposed babies (1.1%) that died in utero was not evaluated but they were at risk of MTCT of HIV. The results of the present study confirmed that adhering to HAART in pregnancy, labor and during breastfeeding by HIV positive mothers can result in virtual eMTCT of <2% even in developing countries like Nigeria where breastfeeding and vaginal delivery are the norms. The findings of this study is similar to the MTCT rate of 0.0% and 1.1% reported in Ouagadougou, Burkina Faso and Maiduguri, Nigeria, respectively for HIV positive mothers on HAART.[1718] In Orlu, Imo state, Nigeria, a MTCT rate of 13.6% was reported in unbooked HIV positive mothers who had no form of ART.[19] Virtual eMTCT of HIV requires simpler, safe, and effective ART regimen like the WHO Option B+ which is a lifelong HAART regimen that can be administered by nurses at the community levels. The WHO Option B+ as currently practiced in the study center has the added advantages of reducing maternal morbidity and mortality, preventing the development of drug resistance, preventing new HIV transmission during breastfeeding and in discordant couples.[15] The overall good result reported in this study could be attributed to the adoption of the WHO Option B+ protocol in addition to the quality of HIV testing and counseling, and follow-up by the PMTCT nursing staff and treatment specialists in the center. HIV viral load and retroviral drug sensitive testing are very important components of ART and should also be made universally accessible as well as HAART to every HIV positive mothers. This will help in monitoring maternal response to ARV drugs and ultimately the suppression of maternal viral replication, which is the goal of any modern PMTCT intervention strategy.[1415] Maternal HAART initiated during pregnancy and continued through breastfeeding periods and for life as done in this study has been proven to be a culturally acceptable and non-stigmatizing safe breastfeeding option in the developing countries where safe water, electricity and uninterrupted supplies of breast-milk substitutes are not always available.[15] In view of the possibility of “window period” associated with HIV infection, re-testing for HIV at 28-36 weeks gestation was done for all the mothers who had tested negative at booking. The challenges of PMTCT observed in this report included the absence of facilities for measuring maternal viral load, which determines the extent of suppression of maternal viral replication, and also lack of the infant PCR diagnostic test, which necessitated referral to another center for early diagnosis of pediatric HIV infections. The limitations of this study include the fact that it involved only the HIV positive women that booked for antenatal care in the tertiary institution. These women are likely to be wealthier and more educated than the general population and hence more likely to adhere to HAART and other PMTCT interventions. The sample size of 184 for the exposed babies seems small to make generalization to the entire population. The data on infant feeding methods was based on maternal recall, and hence we cannot exclude the possibility of recall bias.

Conclusion/Recommendation

With adequate provision of HAART to all HIV infected pregnant women for life, virtual elimination of MTCT and thus pediatric HIV infections is possible in a society where infant breast feeding and vaginal delivery are the norms. Government commitment and financial support are critical for future sustainability of the currently United States of American government-driven HIV/AIDS projects.
  14 in total

1.  The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria.

Authors:  C M Chama; M Bello; B A Ajayi; S Zarma; W Gashau
Journal:  J Obstet Gynaecol       Date:  2010-05       Impact factor: 1.246

2.  Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.

Authors:  Isabelle de Vincenzi
Journal:  Lancet Infect Dis       Date:  2011-01-13       Impact factor: 25.071

3.  Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

Authors: 
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

4.  Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1.

Authors:  B H Tess; L C Rodrigues; M L Newell; D T Dunn; T D Lago
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

5.  Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy.

Authors:  B J Simpson; E D Shapiro; W A Andiman
Journal:  Pediatr Infect Dis J       Date:  2000-07       Impact factor: 2.129

6.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.

Authors:  Marc Lallemant; Gonzague Jourdain; Sophie Le Coeur; Jean Yves Mary; Nicole Ngo-Giang-Huong; Suporn Koetsawang; Siripon Kanshana; Kenneth McIntosh; Vallop Thaineua
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

Review 7.  Preventing mother-to-child HIV transmission in the new millennium: the challenge of breast feeding.

Authors:  Louise Kuhn; Zena Stein; Mervyn Susser
Journal:  Paediatr Perinat Epidemiol       Date:  2004-01       Impact factor: 3.980

8.  Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D.

Authors:  Boris Renjifo; Peter Gilbert; Beth Chaplin; Gernard Msamanga; Davis Mwakagile; Wafaie Fawzi; Max Essex
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

9.  Risk factors for mother-to-child transmission of HIV-1.

Authors: 
Journal:  Lancet       Date:  1992-04-25       Impact factor: 79.321

10.  HIV mother-to-child transmission, mode of delivery, and duration of rupture of membranes: experience in the current era.

Authors:  Siobhan Mark; Kellie E Murphy; Stanley Read; Ari Bitnun; Mark H Yudin
Journal:  Infect Dis Obstet Gynecol       Date:  2012-05-28
View more
  10 in total

1.  Prevention of mother-to-child transmission (PMTCT) of HIV: a review of the achievements and challenges in Burkina-Faso.

Authors:  Laure Stella Ghoma Linguissi; Tani Sagna; Serge Théophile Soubeiga; Luc Christian Gwom; Céline Nguefeu Nkenfou; Dorcas Obiri-Yeboah; Abdoul Karim Ouattara; Virginio Pietra; Jacques Simpore
Journal:  HIV AIDS (Auckl)       Date:  2019-07-24

2.  Integrating gestational diabetes and type 2 diabetes care into primary health care: Lessons from prevention of mother-to-child transmission of HIV in South Africa - A mixed methods study.

Authors:  Jean Claude Mutabazi; Pascal Roland Enok Bonong; Helen Trottier; Lisa Jayne Ware; Shane A Norris; Katherine Murphy; Naomi Levitt; Christina Zarowsky
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

3.  HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.

Authors:  Irene Aguti; Charles Kimbugwe; Patricia Apai; Siraji Munyaga; Richard Nyeko
Journal:  Pan Afr Med J       Date:  2020-12-02

4.  Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria.

Authors:  Babatunde Adelekan; Bidemi Harry-Erin; Martha Okposo; Ahmad Aliyu; Nicaise Ndembi; Patrick Dakum; Nadia A Sam-Agudu
Journal:  PLoS One       Date:  2022-02-14       Impact factor: 3.240

Review 5.  Mother-to-child transmission of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among pregnant women with single, dual or triplex infections of human immunodeficiency virus, hepatitis B virus and hepatitis C virus in Nigeria: A systematic review and meta-analysis.

Authors:  George Uchenna Eleje; Chinyere Ukamaka Onubogu; Preye Owen Fiebai; Ikechukwu Innocent Mbachu; Godwin Otuodichinma Akaba; Olabisi Morebise Loto; Hadiza Abdullahi Usman; Ayyuba Rabiu; Moriam Taiwo Chibuzor; Rebecca Chinyelu Chukwuanukwu; Ngozi Nneka Joe-Ikechebelu; Chike Henry Nwankwo; Stephen Okoroafor Kalu; Chukwuanugo Nkemakonam Ogbuagu; Shirley Nneka Chukwurah; Chinwe Elizabeth Uzochukwu; Ijeoma Chioma Oppah; Aishat Ahmed; Richard Obinwanne Egeonu; Chiamaka Henrietta Jibuaku; Samuel Oluwagbenga Inuyomi; Bukola Abimbola Adesoji; Ubong Inyang Anyang; Uchenna Chukwunonso Ogwaluonye; Ekene Agatha Emeka; Odion Emmanuel Igue; Ogbonna Dennis Okoro; Prince Ogbonnia Aja; Chiamaka Perpetua Chidozie; Hadiza Sani Ibrahim; Fatima Ele Aliyu; Aisha Ismaila Numan; Solace Amechi Omoruyi; Osita Samuel Umeononihu; Chukwuemeka Chukwubuikem Okoro; Ifeanyi Kingsley Nwaeju; Arinze Anthony Onwuegbuna; Eric Okechukwu Umeh; Sussan Ifeyinwa Nweje; Lydia Ijeoma Eleje; Ifeoma Clara Ajuba; David Chibuike Ikwuka; Emeka Philip Igbodike; Chisom God'swill Chigbo; Uzoamaka Rufina Ebubedike; Chigozie Geoffrey Okafor; Nnaedozie Paul Obiegbu; Ibrahim Adamu Yakasai; Oliver Chukwujekwu Ezechi; Joseph Ifeanyichukwu Ikechebelu
Journal:  SAGE Open Med       Date:  2022-04-28

6.  Efficacy of Six-Week Extended-Dose Nevirapine Varies by Infant Birth Weight with Greatest Relative Efficacy in Low Birth Weight Infants.

Authors:  Nikhil Gupte; Aarti Kinikar; Katherine N McIntire; Ramesh Bhosale; Sandesh Patil; Nishi Suryavanshi; Vidya Mave; Vandana Kulkarni; Robert C Bollinger; Amita Gupta
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

Review 7.  HIV-free survival at 12-24 months in breastfed infants of HIV-infected women on antiretroviral treatment.

Authors:  Lana Clara Chikhungu; Stephanie Bispo; Nigel Rollins; Nandi Siegfried; Marie-Louise Newell
Journal:  Trop Med Int Health       Date:  2016-05-24       Impact factor: 2.622

8.  Pregnancy incidence and intention after HIV diagnosis among women living with HIV in Canada.

Authors:  Kate Salters; Mona Loutfy; Alexandra de Pokomandy; Deborah Money; Neora Pick; Lu Wang; Shahab Jabbari; Allison Carter; Kath Webster; Tracey Conway; Daniele Dubuc; Nadia O'Brien; Karene Proulx-Boucher; Angela Kaida
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

9.  Trends and predictors of mother-to-child transmission of HIV in an era of protocol changes: Findings from two large health facilities in North East Nigeria.

Authors:  Ademola Joshua Itiola; Ameena Ebrahim Goga; Vundli Ramokolo
Journal:  PLoS One       Date:  2019-11-11       Impact factor: 3.240

10.  Evidence of accessibility and utility of point-of-care diagnostics as an integral part of prevention of mother-to-child transmission services: systematic scoping review protocol.

Authors:  Juliet Katoba; Lydia Hangulu; Tivani Phosa Mashamba-Thompson
Journal:  BMJ Open       Date:  2017-11-04       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.